ArticleInternational journal of clinical and experimental medicine2015
Upregulated MiR-1269 in hepatocellular carcinoma and its clinical significance.
Article in International journal of clinical and experimental medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Potential role of microRNA‑223‑3p in the tumorigenesis of hepatocellular carcinoma: A comprehensive study based on data mining and bioinformatics.Molecular medicine reports · 2018Pooled it
- Utility of miR‑133a‑3p as a diagnostic indicator for hepatocellular carcinoma: An investigation combined with GEO, TCGA, meta‑analysis and bioinformatics.Molecular medicine reports · 2018Pooled it
- Downregulation of miR‑136‑5p in hepatocellular carcinoma and its clinicopathological significance.Molecular medicine reports · 2017Pooled it
- Synthetic Circular RNA for microRNA-1269a Suppresses Tumor Progression in Oral Squamous Cell Carcinoma.Cancers · 2024Article
- Article
- Role of RBMS3 Novel Potential Regulator of the EMT Phenomenon in Physiological and Pathological Processes.International journal of molecular sciences · 2022Review
- miR-1269a and miR-1269b: Emerging Carcinogenic Genes of the miR-1269 Family.Frontiers in cell and developmental biology · 2022Review
- The Role of DACT Family Members in Tumorigenesis and Tumor Progression.International journal of biological sciences · 2022Review
- Crystal structure of the GTP-binding protein-like domain of AGAP1.Acta crystallographica. Section F, Structural biology communications · 2021Article
- Association between Genetic Polymorphisms of miR-1307, miR- 1269, miR-3117 and Breast Cancer Risk in a Sample of South East Iranian Women.Asian Pacific journal of cancer prevention : APJCP · 2021Article
- Clinical Value and Potential Mechanism of miRNA-33a-5p in Lung Squamous Cell Carcinoma.Analytical cellular pathology (Amsterdam) · 2021Article
- Downregulation of miRNA-126-3p is associated with progression of and poor prognosis for lung squamous cell carcinoma.FEBS open bio · 2020Article
- Identification of high expression profiles of miR-31-5p and its vital role in lung squamous cell carcinoma: a survey based on qRT-PCR and bioinformatics analysis.Translational cancer research · 2019Article
- Potential ceRNA networks involved in autophagy suppression of pancreatic cancer caused by chloroquine diphosphate: A study based on differentially‑expressed circRNAs, lncRNAs, miRNAs and mRNAs.International journal of oncology · 2019Article
- MicroRNA-1269 promotes cell proliferation via the AKT signaling pathway by targeting RASSF9 in human gastric cancer.Cancer cell international · 2019Article
- The clinicopathological significance of decreased miR-125b-5p in hepatocellular carcinoma: evidence based on RT-qPCR, microRNA-microarray, and microRNA-sequencing.International journal of clinical and experimental pathology · 2019Article
- Clinical value of miR-182-5p in lung squamous cell carcinoma: a study combining data from TCGA, GEO, and RT-qPCR validation.World journal of surgical oncology · 2018Article
- The SNPs in pre-miRNA are related to the response of capecitabine-based therapy in advanced colon cancer patients.Oncotarget · 2018Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesMicroRNAs (miRNAs) are small, non-coding RNAs that have been increasingly shown important roles in various classes of cancers. However, miR-1269 has not been comprehensively studied in hepatocellular carcinoma (HCC). Thus, the purpose of the study was to evaluate the relationship between the expression of miR-1269 and clinicopathological parameters in HCC patients, and to predict its potential target genes.
methodsTotal RNA was extracted from 95 pairs of HCC and matching adjacent non-cancerous tissues. The level of miR-1269 expression was detected by using quantitative real-time RT-PCR and calculated with the 2(-ΔCq) method. Eighteen online biological databases were used for targets prediction.
resultsMiR-1269 expression was up-regulated in HCC tissues (1.9264±0.7160) compared to their non-tumor livers (1.5518±0.7273, P < 0.001). Level of miR-1269 was positively correlated to tumor nodes (r = 0.206, P = 0.046), metastasis (r = 0.203, P = 0.049), portal vein tumor embolus (r = 0.247, P = 0.016), vaso-invasion (r = 0.273, P = 0.008), tumor capsular infiltration (r = 0.407, P < 0.001) and expression of MTDH (r = 0.211, P = 0.005). Finally, 7 databases could be applied for the target prediction successfully. There were 9 targeted genes which had been shown concurrently by at least 4 databases: AGAP1, AGK, BPTF, C16orf74, DACT1, LIX1L, RBMS3, ZNF706 and BMPER.
conclusionsMiR-1269 may be possibly involved in the tumorigenesis and progress of HCC. MiR-1269 could also act as a potential biomarker for the prognosis prediction for HCC.
Indexed as
Identifiers
25785048PMC4358503What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.